"Pyrimidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
| Descriptor ID |
D011743
|
| MeSH Number(s) |
D03.383.742
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidines".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidines".
This graph shows the total number of publications written about "Pyrimidines" by people in this website by year, and whether "Pyrimidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 4 | 4 |
| 2003 | 5 | 2 | 7 |
| 2004 | 7 | 3 | 10 |
| 2005 | 3 | 1 | 4 |
| 2006 | 4 | 2 | 6 |
| 2007 | 6 | 4 | 10 |
| 2008 | 9 | 2 | 11 |
| 2009 | 2 | 2 | 4 |
| 2010 | 7 | 2 | 9 |
| 2011 | 10 | 10 | 20 |
| 2012 | 4 | 5 | 9 |
| 2013 | 10 | 8 | 18 |
| 2014 | 9 | 5 | 14 |
| 2015 | 7 | 6 | 13 |
| 2016 | 16 | 7 | 23 |
| 2017 | 6 | 12 | 18 |
| 2018 | 18 | 8 | 26 |
| 2019 | 5 | 6 | 11 |
| 2020 | 7 | 10 | 17 |
| 2021 | 4 | 6 | 10 |
| 2022 | 1 | 11 | 12 |
| 2023 | 3 | 5 | 8 |
| 2024 | 4 | 9 | 13 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 Feb 06; 145(6):612-624.
-
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions. Clin Cancer Res. 2025 Feb 03; 31(3):561-572.
-
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2025 Feb 03; 31(3):479-490.
-
Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. Oncologist. 2025 Jan 17; 30(1).
-
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 01; 110(1):92-102.
-
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024 Dec 26; 144(26):2706-2717.
-
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood. 2024 Dec 19; 144(25):2678-2681.
-
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol Oncol. 2024 Dec 18; 17(1):125.
-
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid. 2025 Jan; 35(1):6-17.
-
Ten years of experience with ruxolitinib since approval for polycythemia vera: A review of clinical efficacy and safety. Cancer. 2025 Jan 01; 131(1):e35661.